Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients

Coronavirus disease 2019 (COVID-19) is a highly infectious respiratory disease caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has been observed to vary in its degree of symptoms. One of the most important clinical manifestations is pneumonia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bogna Grygiel-Górniak, Osama Shaikh, Nikita Niranjan Kumar, Shao Heng Hsu, Włodzimierz Samborski
Formato:	article
Lenguaje:	EN
Publicado:	Termedia Publishing House 2021
Materias:	rheumatic diseases tocilizumab coronavirus disease 2019. Medicine R
Acceso en línea:	https://doaj.org/article/76f5289ab74b4934bde3bedbbad502ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:76f5289ab74b4934bde3bedbbad502ab
record_format	dspace
spelling	oai:doaj.org-article:76f5289ab74b4934bde3bedbbad502ab2021-12-02T18:55:18ZUse of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients0034-62332084-983410.5114/reum.2021.108554https://doaj.org/article/76f5289ab74b4934bde3bedbbad502ab2021-08-01T00:00:00Zhttps://www.termedia.pl/Use-of-the-rheumatic-drug-tocilizumab-for-treatment-of-SARS-CoV-2-patients,18,44953,1,1.htmlhttps://doaj.org/toc/0034-6233https://doaj.org/toc/2084-9834Coronavirus disease 2019 (COVID-19) is a highly infectious respiratory disease caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has been observed to vary in its degree of symptoms. One of the most important clinical manifestations is pneumonia and the subsequent worsening of the hyperinflammatory state and cytokine storm. Tocilizumab (TCB) is a recombinant humanized, anti-human monoclonal antibody of the immunoglobulin G1k (IgG1k) subclass that acts against soluble and membrane-bound interleukin six receptors (IL-6R). There is wide use of TCB in rheumatic diseases. However, recently this medication has been used in the treatment of SARS-CoV-2 infection. Tocilizumab application in COVID-19 patients with a high risk of a cytokine storm shows a positive response in reducing the mortality rate. Moreover, TCB minimizes the time needed to recover, improves oxygenation, shortens the duration of vasopressor support, and reduces the likelihood of invasive mechanical ventilation. Therefore we provide an overview of recent studies to understand the efficacy of this drug under various circumstances, including COVID-19 and rheumatic pathologies. This article also explores and integrates the different treatment possibilities in prominent anti-inflammatory and immune-modulatory-related symptoms. The preliminary data demonstrate promising results regarding the efficacy of TCB use in severe COVID-19 patients. Nevertheless, randomized controlled trials, with adequate sample sizes and sufficient follow-up periods, are needed to form conclusions and establish treatment recommendations.Bogna Grygiel-GórniakOsama ShaikhNikita Niranjan KumarShao Heng HsuWłodzimierz SamborskiTermedia Publishing Housearticlerheumatic diseases tocilizumab coronavirus disease 2019.MedicineRENRheumatology, Vol 59, Iss 4, Pp 252-259 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rheumatic diseases tocilizumab coronavirus disease 2019. Medicine R
spellingShingle	rheumatic diseases tocilizumab coronavirus disease 2019. Medicine R Bogna Grygiel-Górniak Osama Shaikh Nikita Niranjan Kumar Shao Heng Hsu Włodzimierz Samborski Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
description	Coronavirus disease 2019 (COVID-19) is a highly infectious respiratory disease caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has been observed to vary in its degree of symptoms. One of the most important clinical manifestations is pneumonia and the subsequent worsening of the hyperinflammatory state and cytokine storm. Tocilizumab (TCB) is a recombinant humanized, anti-human monoclonal antibody of the immunoglobulin G1k (IgG1k) subclass that acts against soluble and membrane-bound interleukin six receptors (IL-6R). There is wide use of TCB in rheumatic diseases. However, recently this medication has been used in the treatment of SARS-CoV-2 infection. Tocilizumab application in COVID-19 patients with a high risk of a cytokine storm shows a positive response in reducing the mortality rate. Moreover, TCB minimizes the time needed to recover, improves oxygenation, shortens the duration of vasopressor support, and reduces the likelihood of invasive mechanical ventilation. Therefore we provide an overview of recent studies to understand the efficacy of this drug under various circumstances, including COVID-19 and rheumatic pathologies. This article also explores and integrates the different treatment possibilities in prominent anti-inflammatory and immune-modulatory-related symptoms. The preliminary data demonstrate promising results regarding the efficacy of TCB use in severe COVID-19 patients. Nevertheless, randomized controlled trials, with adequate sample sizes and sufficient follow-up periods, are needed to form conclusions and establish treatment recommendations.
format	article
author	Bogna Grygiel-Górniak Osama Shaikh Nikita Niranjan Kumar Shao Heng Hsu Włodzimierz Samborski
author_facet	Bogna Grygiel-Górniak Osama Shaikh Nikita Niranjan Kumar Shao Heng Hsu Włodzimierz Samborski
author_sort	Bogna Grygiel-Górniak
title	Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
title_short	Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
title_full	Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
title_fullStr	Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
title_full_unstemmed	Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
title_sort	use of the rheumatic drug tocilizumab for treatment of sars-cov-2 patients
publisher	Termedia Publishing House
publishDate	2021
url	https://doaj.org/article/76f5289ab74b4934bde3bedbbad502ab
work_keys_str_mv	AT bognagrygielgorniak useoftherheumaticdrugtocilizumabfortreatmentofsarscov2patients AT osamashaikh useoftherheumaticdrugtocilizumabfortreatmentofsarscov2patients AT nikitaniranjankumar useoftherheumaticdrugtocilizumabfortreatmentofsarscov2patients AT shaohenghsu useoftherheumaticdrugtocilizumabfortreatmentofsarscov2patients AT włodzimierzsamborski useoftherheumaticdrugtocilizumabfortreatmentofsarscov2patients
_version_	1718377275016085504

Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients

Ejemplares similares